M. Cespon

Statistics

Publications

Citations

105

H-Index

Active since

2003

Affiliations

Vanderbilt-Ingram Cancer Center(Current)

Memorial Sloan Kettering Cancer Center

M. Cespon is an author at Vanderbilt-Ingram Cancer Center specializing in pharmacology, epidermal growth factor receptor inhibition, and erlotinib therapy.

Publications per year

2003–2004

Publications

Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC)

Mark G. Kris, Alan Sandler, V.A. Miller et al. · Journal of Clinical Oncology · 2004 · 72 citations

Medicine, Oncology, Pharmacology +15

Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC)

Mark G. Kris, Alan Sandler, Virginia L. Miller et al. · Journal of Clinical Oncology · 2004 · 19 citations

Medicine, Oncology, Pharmacology +15

54 The epidermal growth factor receptor tyrosine kinase inhibitor, eriotinib (Tarceva TM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: interim results of a phase II trial

Jasmine Patel, V.A. Miller, Mark G. Kris et al. · European Journal of Cancer Supplements · 2003 · 14 citations

Medicine, Oncology, Pharmacology +16

1–3 of 3